As we begin June, we review moves from smid-cap biopharma companies during this past week as well as in May. See Table 1 for weekly moves, May moves, and moves YTD for companies and categories on BPIQ.com compared to XBI. Excellent finish to make this one of the better weeks for biotech investors this year. We're currently running a 40% OFF ASCO sale, learn more here.
Table 1. BPIQ company weekly/monthly moves and YTD moves
Category | Weekly Move (5/30-6/3) | May Move | YTD Move |
|---|---|---|---|
All BPIQ Companies | +0.71% | -9.09% | -45.81% |
CAR-T Companies | +1.82% | -6.14% | -52.19% |
Gene Editing Companies | 1.09% | ​-5.89% | -55.15% |
XBI | +0.17% | -6.84% | -36.4% |
See the biggest moves from last week below:
Don't miss upcoming catalysts.. Get our weekly Catalyst Watchlist Free!
*We never send you spam - unsubscribe anytime
Highlights for the week and month
ASCO
ASCO abstracts and additional data were released as scheduled. See our separate ASCO post on this key annual cancer meeting, including updated info on big stock movers on abstract release.
ASCO started today (6/3) and continues through 6/7
Biggest positive move (week of 5/30-6/3)
#TXMD +364% TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD.
Biggest positive move (month of May)
#CBIO +158% Catalyst Biosciences Sells Complement Portfolio for $60 Million
Biggest negative move (week of 5/30-6/3)
#AGLE -60.5% Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency
Biggest negative move (month of May)
#EVFM -86.4% Evofem Biosciences Announces Pricing of Approximately $26.6 Million Public Offering
Additional weekly big moves
#TPTX +106% Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
#VTVT +58% VTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare.
#DTIL +17% Precision BioSciences to Provide an Update on its Ongoing Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on Wednesday, June 8, 2022.
#IOVA +18.9% Iovance Biotherapeutics Up 16% After Insiders Buy Shares
#NRIX +16.3% Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs at the Annual Meeting of the American Society of Clinical Oncology (ASCO).
#CNCE +16% CONCERT PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
#VECT +5% VectivBio Announces First Two Patients Dosed in Phase 2 STARGAZE Study of Apraglutide for the Treatment of Acute Graft-versus-Host Disease
#HCM -7% HUTCHMED Announces TAZVERIK® Approved to be Used in Hainan Pilot Zone in China.
#PDSB -13% PDS Biotech Announces Expansion of its VERSATILE-002 Clinical Trial into Europe
#NVAX -21% Novavax Statement on US FDA Briefing Document Related to Myocarditis/Pericarditis
#TGTX -34% TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS.
#OTLK -34% Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD
#TNXP -39% Tonix Pharmaceuticals Announces Issuance of U.S. Patent for TNX-801 Smallpox and Monkeypox Vaccine and Recombinant Pox Virus (RPV) Platform Technology.
#CNTA -42% Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
#IMUX -45% Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update source
Additional monthly big moves
#CNCE +103.2% Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
#BMEA +83% Biomea Fusion Reports First Quarter 2022 Financial Results and Business Highlights
#ONCT +74.1% Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022
#SPRO -75.7% Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline
#GNCA -78.6% Genocea Announces Wind Down of Operations and Delisting From NASDAQ
Highlights for next week
To see next week's Big Movers HERE, subscribe. Learn more here.
$PDSB PDS0101 updates
$PBYI Neratinib data
$BLUE AdComm meetings
ASCO started today (6/3)
See our Separate ASCO post for more details about this key annual cancer biopharma meeting
See our Big Movers post to learn about upcoming Movers throughout June and PDUFAs, after subscribing. Learn more here.